Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apricoxib + lapatinib + capecitabine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apricoxib + lapatinib + capecitabine is an investigational combination therapy studied for the treatment of advanced or metastatic HER2-positive breast cancer. Lapatinib is a small molecule, oral, reversible dual tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2), interfering with tumor cell proliferation and survival[6][7]. Capecitabine is an oral prodrug of 5-fluorouracil, a cytotoxic antimetabolite that inhibits DNA synthesis in rapidly dividing cells. Apricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor under investigation for its potential to enhance the efficacy of anticancer regimens by modulating inflammation and tumor microenvironment. The combination has been evaluated in phase 2 clinical trials for patients with HER2-positive breast cancer who have progressed on prior therapies[2].
- Other names
- GW572016 (for lapatinib)
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on apricoxib + lapatinib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apricoxib + lapatinib + capecitabine.